Sanara MedTech
Sanara MedTech Inc. develops and commercializes technologies to improve clinical outcomes and reduce healthcare costs in the surgical, non-healing ulcer, and skin care markets. The company offers a wide range of surgical and wound care products, and focuses on research and development through its division, Rochal Technologies.
Company Overview of Sanara MedTech
Sanara MedTech Inc. is dedicated to developing and commercializing innovative technologies aimed at improving clinical outcomes while reducing healthcare costs. The company operates primarily in the surgical, non-healing ulcer, and skincare markets. Focused on providing cutting-edge solutions, Sanara MedTech aims to enhance patient care and support healthcare professionals across various specialties.
Surgical Products Offered by Sanara MedTech
Sanara MedTech provides a range of advanced surgical products aimed at supporting various clinical needs. These products include the CellerateRX® Surgical Powder, which aids in surgical wound management through hydrolyzed collagen. The FORTIFY TRG® Tissue Repair Graft, made from porcine small intestinal submucosa (SIS), reinforces soft tissue. The FORTIFY FLOWABLE® Extracellular Matrix, TEXAGEN® Amniotic Membrane Allograft, and the ALLOCYTE® Plus Advanced Viable Bone Matrix cater to different types of wounds and tissue needs. The BiFORM® Bioactive Moldable Matrix and BIASURGE™ Advanced Surgical Solution further support bone and wound care.
Sanara MedTech Wound Care Products
Sanara MedTech's wound care portfolio includes BIAKŌS™ ANTIMICROBIAL SKIN & WOUND CLEANSER and IRRIGATION SOLUTION, which help cleanse and irrigate wounds by eliminating biofilms and microbes. The BIAKŌS™ ANTIMICROBIAL WOUND GEL targets biofilm microbes, aiding in wound healing. HYCOL® HYDROLYZED COLLAGEN benefits from hydrolyzed collagen fragments for better wound care. Additionally, the CellerateRX® Gel addresses various wound types, offering solutions for dry to moderately exudating wounds.
Research and Development at Sanara MedTech
Sanara MedTech's R&D division, Rochal Technologies, focuses on advancing wound and skin care innovations from concept to commercialization. The research efforts include areas like biofilm removal, negative pressure adjuncts, advanced biologics, oxygen enhancement, hydrolyzed collagen, and debridement techniques. This division plays a key role in maintaining Sanara MedTech's innovative edge in the clinical market.
Acquisition of Scendia Biologics by Sanara MedTech
Sanara MedTech expanded its product portfolio through the acquisition of Scendia Biologics, a supplier of orthobiologic and soft tissue-focused products. Scendia Biologics operates a state-licensed and FDA-registered tissue bank, providing hospitals, surgery centers, and clinicians with allograft tissue-based products. This acquisition enhances Sanara MedTech's capabilities in delivering comprehensive solutions to healthcare providers.